Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Wave Life Sciences (WVE) EBITDA (2016 - 2025)

Historic EBITDA for Wave Life Sciences (WVE) over the last 11 years, with Q3 2025 value amounting to -$53.9 million.

  • Wave Life Sciences' EBITDA rose 1261.6% to -$53.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$122.0 million, marking a year-over-year increase of 1439.85%. This contributed to the annual value of -$97.1 million for FY2024, which is 6863.28% down from last year.
  • As of Q3 2025, Wave Life Sciences' EBITDA stood at -$53.9 million, which was up 1261.6% from -$50.4 million recorded in Q2 2025.
  • In the past 5 years, Wave Life Sciences' EBITDA registered a high of $29.2 million during Q4 2024, and its lowest value of -$61.7 million during Q3 2024.
  • Moreover, its 5-year median value for EBITDA was -$37.9 million (2022), whereas its average is -$31.1 million.
  • Examining YoY changes over the last 5 years, Wave Life Sciences' EBITDA showed a top increase of 27996.05% in 2024 and a maximum decrease of 95401.66% in 2024.
  • Wave Life Sciences' EBITDA (Quarter) stood at -$34.9 million in 2021, then fell by 25.11% to -$43.6 million in 2022, then skyrocketed by 62.86% to -$16.2 million in 2023, then surged by 279.96% to $29.2 million in 2024, then crashed by 284.84% to -$53.9 million in 2025.
  • Its EBITDA was -$53.9 million in Q3 2025, compared to -$50.4 million in Q2 2025 and -$46.8 million in Q1 2025.